IGC Announces Financial Results For Quarter Ended June 30, 2017

BETHESDA, Md., Aug. 21, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE AMERICAN:IGC) announces financial results for the quarter ended June 30, 2017.

"During the quarter, we secured an IP licensing agreement from the University of South Florida addressing a potential treatment for Alzheimer's disease.  This patent filing claims discovery of a new pathway: low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is what occurs in Alzheimer's disease and causes cognitive decline.  IGC expects to release mouse data showing that this pathway and therapy have possible blockbuster potential in treating Alzheimer's disease.  We expect to take this exciting treatment to human medical trials as soon as possible," stated Ram Mukunda, CEO of IGC.

Total revenue was $52,926 for the three months ended June 30, 2017, as compared to $288,493 for the three months ended June 30, 2016. The decrease in revenue is attributable to the corporate mandate to extricate IGC from the electronic and iron ore trading businesses and focus management on medical cannabis therapies. The revenue in the three months ended June 30, 2017 is all from the rental of heavy equipment and real estate management.

Selling, general and administrative expenses were $436,351 for the quarter ended June 30, 2017 as compared to $307,772 for the quarter ended June 30, 2016.  Most of these expenses are a result of public-company expenses, including legal fees.

The Company reported a consolidated GAAP net income loss of $432,141 and a GAAP EPS loss of $0.02 compared to a GAAP net income loss of $383,566 and a GAAP EPS loss of $0.02 for the three months ended June 30, 2016. The increase in loss is due to increased SG&A related to marketing programs that the company initiated.

For the quarter ended June 30, 2017, our non-GAAP cash burn was approximately $389,577.

At the end of June 30, 2017, our cash and cash equivalents along with restricted cash was $345,610 with working capital of $623,984. We anticipate securing additional capital to further our patent portfolio and commence medical trials on our Alzheimer's product.

About IGC

IGC develops cannabis-based combination therapies to treat Alzheimer's, pain, nausea, eating disorders, several end points of Parkinson's, and epilepsy in humans, dogs and cats.  In support of this effort, IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. We are based in Bethesda, Maryland.

Our website: www.igcinc.us.  Twitter @IGCIR Facebook.com/IGCIR/

Forward-looking Statements

Please see forward-looking statements as discussed in detail in IGC's Form 10-K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

FINANCIAL STATEMENTS TO FOLLOW

INDIA GLOBALIZATION CAPITAL, INC. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS  
   
(All amounts in USD, except number of shares and per share amounts)  
   
    As of  
    30-June-17     31-Mar-17  
    (unaudited)     (audited)  
ASSETS            
Current assets:            
Cash and cash equivalents   $ 345,610     $ 538,029  
Accounts receivable, net of allowances     839,462       752,926  
Prepaid expenses and other current assets     416,160       410,408  
Short-term investments     -       1,880,000  
Total current assets   $ 1,601,232     $ 3,581,363  
Goodwill     198,169       198,169  
Property, plant and equipment, net     952,009       953,936  
Investments in affiliates     773,111       773,111  
Investments-others     5,239,778       5,238,003  
Other non-current assets     672,142       539,720  
Total long-term assets   $ 7,835,209     $ 7,702,939  
Total assets   $ 9,436,441     $ 11,284,302  
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current liabilities:                
Trade payables     427,079       416,532  
Accrued expenses     143,000       181,465  
Other current liabilities     407,169       691,714  
Total current liabilities   $ 977,248     $ 1,289,711  
Long -term borrowings     175,991       452,080  
Loans - others     388,476       392,226  
Notes payable     1,800,000       1,800,000  
Total non-current liabilities   $ 2,364,467     $ 2,644,306  
Total liabilities   $ 3,341,715     $ 3,934,017  
Stockholders' equity:                
Common stock — $.0001 par value; 150,000,000 shares authorized; 23,265,531 issued and outstanding as of March 31, 2017 and 26,803,020 issued and outstanding as of June 30, 2017.   $ 2,680     $ 2,827  
Additional paid-in capital     60,588,461       61,413,533  
Accumulated other comprehensive income     (2,046,023 )     (2,047,780 )
Retained earnings (Deficit)     (52,441,602 )     (52,009,459 )
Total equity attributable to Parent   $ 6,103,516     $ 7,359,121  
Non-controlling interest   $ (8,790 )   $ (8,836 )
Total stockholders' equity   $ 6,094,726     $ 7,350,285  
Total liabilities and stockholders' equity   $ 9,436,441     $ 11,284,302  
   
See accompanying Notes to Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements contained in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.  
   

INDIA GLOBALIZATION CAPITAL, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF OPERATIONS  
(Unaudited)  
   
(All amounts in USD, except number of shares and per share amounts)  
   
    As of  
    Three months ended June 30,  
    2017     2016  
             
Revenues   $ 52,926     $ 288,493  
Cost of revenues (excluding depreciation)     (6,880 )     (201,854 )
Selling, general and administrative expenses     (436,351 )     (307,772 )
Depreciation     (5,964 )     (97,672 )
Operating income (loss)   $ (396,269 )   $ (318,805 )
Interest expense     (44,546 )     (43,278 )
Other income, net     8,355       1,755  
Income before income taxes and minority interest attributable to non-controlling interest   $ (432,460 )   $ (360,328 )
Income taxes benefit/ (expense)     -       -  
Net income/(loss)   $ (432,460 )   $ (360,328 )
Non-controlling interests in earnings of subsidiaries     (319 )     23,238  
Net income / (loss) attributable to common stockholders   $ (432,141 )   $ (383,566 )
Earnings/(loss) per share attributable to common stockholders:          
Basic   $ (0.02 )   $ (0.02 )
Diluted   $ (0.02 )   $ (0.02 )
Weighted-average number of shares used in computing earnings per share amounts:  
Basic     25,865,307       23,312,056  
Diluted     25,865,307       23,312,056  
   
See accompanying Notes to Consolidated Financial Statements below in this report and Notes to the Audited Consolidated Financial Statements contained in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2017 filed with the SEC on July 14, 2017.  

ContactClaudia Grimaldi301-983-0998

Primary Logo

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX